 SAN FRANCISCO, Dec. 07, 2020 GLOBE NEWSWIRE -- Olema Pharmaceuticals, Inc. Olema or Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for womens cancers, today announced two posters relating to OP-1250, a complete estrogen receptor ER antagonist CERAN and a selective ER degrader SERD, will be presented at the San Antonio Breast Cancer Symposium SABCS, to be held virtually from December 8-11, 2020. 